(RTTNews) - Artelo Biosciences (ARTL) announced the FDA has issued a Study May Proceed letter for the Investigational New Drug application for ART26.12, for the treatment of chemotherapy-induced peripheral neuropathy. The company said the FDA clearance of the ART26.12 IND application enables it to initiate first-in-human Phase 1 single ascending dose study. The company expects phase 1 trial results in the first half of 2025.
Gregory Gorgas, President and CEO of Artelo Biosciences, said: "We look forward to sharing the initial clinical results with ART26.12 next year."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
